

5. Meisner M, Tschalkowsky K, Hutzler A, Schick C, Schüttler J. Postoperative plasma concentrations of procalcitonin after different types of surgery. *Intensive Care Med* 1998;24:680–684.
6. Bertsch T, Richter A, Hofheinz H, Böhm C, Hartel M, Aufenanger J. Procalcitonin: a new marker for acute phase reaction in acute pancreatitis [in German]. *Langenbecks Arch Chir* 1997;382:367–372.
7. Luo XL, Yang TL, Chen XP, Li YJ. Association of CALCA genetic polymorphism with essential hypertension. *Chin Med J (Engl)* 2008;121:1407–1410.
8. Lemos C, Mendonça D, Pereira-Monteiro J, Barros J, Sequeiros J, Alonso I, Sousa A. BDNF and CGRP interaction: implications in migraine susceptibility. *Cephalalgia* 2010;30:1375–1382.
9. Schoe A, Schippers EF, Ebmeyer S, Struck J, Klautz RJ, de Jonge E, van Dissel JT. Predicting mortality and morbidity after elective cardiac surgery using vasoactive and inflammatory biomarkers with and without the EuroSCORE model. *Chest* 2014;146:1310–1318.
10. Hildebrand F, Kalmbach M, Kaapke A, Krettek C, Stuhmann M. No association between CALCA polymorphisms and clinical outcome or serum procalcitonin levels in German polytrauma patients. *Cytokine* 2009;47:30–36.

Copyright © 2016 by the American Thoracic Society

## Novel Genetic Susceptibility Loci for FEV<sub>1</sub> in the Context of Occupational Exposure in Never-Smokers

To the Editor:

Recently, we identified several novel and plausible genetic susceptibility loci for impaired lung function levels in the context of occupational exposure in a sample, including both never- and ever-

This study is sponsored by grant number 4.1.13.007 of the Lung Foundation Netherlands. K.d.J. and D.A.v.d.P. are supported by grant number 4.113.007 from the Lung Foundation Netherlands. The LifeLines cohort study was supported by the Dutch Ministry of Health, Welfare and Sport; the Ministry of Economic Affairs, Agriculture and Innovation; the province of Groningen; the European Union (regional development fund); the Northern Netherlands Provinces; the Netherlands Organization for Scientific Research; University Medical Center Groningen; University of Groningen, de Nierstichting (the Dutch Kidney Foundation); and the Diabetes Fonds (the Diabetic Foundation). The Vlagtwedde-Vlaardingen cohort study was supported by the Ministry of Health and Environmental Hygiene of the Netherlands and the Netherlands Asthma Fund (grant 187) and the Netherlands Asthma Fund (grant 3.2.02.51), the Stichting Astma Bestrijding, BBMRI-NL (Complementation project), and the European Respiratory Society chronic obstructive pulmonary disease research award 2011 to H.M.B. The lung tissue database was funded by Merck Research Laboratories. The lung eQTL study at Laval University was supported by the Fondation de l'Institut universitaire de cardiologie et de pneumologie de Québec, the Respiratory Health Network of the Fonds de Recherche du Québec-Santé, and the Canadian Institutes of Health Research (MOP - 123369). Y.B. holds a Canada Research Chair in Genomics of Heart and Lung Diseases. The sponsors of this study had no role in the design of the current study, data collection, analysis, and interpretation, or in writing and submitting of the manuscript.

Author Contributions: K.d.J. participated in the study design, analysis and interpretation of the data, and drafting of the manuscript, tables, and figures; H.M.B. and D.S.P. obtained funding; H.M.B., D.S.P., J.M.V., D.A.v.d.P., and I.N. participated in determining the study design and interpretation of data; W.T., Y.B., D.S.P., and A.F. were involved in the design, data collection, and analysis within the lung eQTL database; H.K. designed and provided the job exposure matrix (ALOHA+ JEM) for occupational exposure assessment; and all authors read and approved the final version of the manuscript.

smokers (1). Previous studies suggest that effects of genetic variants (2), occupational exposures (3), and their interactions (1) may be different in never-smokers and ever-smokers. Yet never-smokers generally make up a smaller proportion of subjects in general population studies (including current, former, and never-smokers), and effects solely present in never-smokers may therefore not be detected. Hence, to unravel why and how never-smokers develop impaired lung function levels and chronic respiratory diseases such as chronic obstructive pulmonary disease, it is important to study the effects of nonsmoking-related exposures without potential interference of tobacco smoke exposure. With the current genome-wide interaction study, we aimed to identify novel genetic susceptibility loci for impaired levels of FEV<sub>1</sub> in the context of occupational exposure to biological dust, mineral dust, and gases/fumes in a sample including never-smokers only.

We included never-smokers from two Dutch general population-based cohorts: LifeLines (N = 5,070) and Vlagtwedde-Vlaardingen (N = 431). First, in each cohort separately, genome-wide single-nucleotide polymorphism (SNP)-by-exposure interactions were assessed, using linear regression models specified as follows: FEV<sub>1</sub> = SNP (additive effect) + low exposure + high exposure + SNP × low exposure + SNP × high exposure + sex + age + height. To have a clear exposure contrast, we focused on the SNP-by-high exposure interaction only. Subsequently, the SNP-by-high exposure interactions from both cohorts were metaanalyzed using effects estimates weighted by the SEs. SNPs with interaction *P* values < 5 × 10<sup>-8</sup> and with the same direction of interaction in both cohorts were taken further for cis-acting expression quantitative trait loci (cis-eQTL) analysis in lung tissue of 1,087 subjects (4). Finally, we performed pathway analyses using all SNPs (5). More detailed information about the cohorts, phenotyping, genotyping, occupational exposure assessment, cis-eQTL, and pathway analysis can be found elsewhere (1).

Subjects included from the LifeLines study had a median age of 46 years (range, 18–90 yr), with a mean FEV<sub>1</sub> of 104% predicted and mean FEV<sub>1</sub>/FVC of 78%. Subjects from the Vlagtwedde-Vlaardingen study had a median age of 54 years (range, 36–79 yr), with a mean FEV<sub>1</sub> of 98% predicted and mean FEV<sub>1</sub>/FVC of 76%.

We identified four significant SNP-by-high exposure interactions, one with mineral dust and three with gases/fumes exposure (Table 1). No significant interactions were found with high exposure to biological dust. For all four SNPs, highly exposed subjects had substantially lower FEV<sub>1</sub> levels compared with subjects without exposure, yet only when carrying at least one copy of the risk allele and not when carrying the wild-type genotype (Figures 1A–1D). None of the four identified SNPs was a cis-eQTL in lung tissue. Finally, the Biocarta pathways patched 1 and the natural killer cells were suggestively associated (false discovery rate *P* value < 0.25) with FEV<sub>1</sub> in the context of mineral dust and gases/fumes exposure, respectively.


The most significant interaction identified was between gases/fumes exposure and SNP rs10223081 located nearby the gene *NMUR2*, a G coupled-protein receptor for neuromedin U (NMU) (6). NMU can induce mast cell degranulation leading to, for example, early-phase inflammation, such as neutrophil infiltration in inflamed sites (7), and can induce eosinophil infiltration in allergic inflammatory sites in an antigen-induced asthma model. We found modest expression of *NMUR2* in lung tissue (data not shown), yet this expression was not associated with the identified SNP. Importantly, effects of high exposure on gases/fumes were large and of

**Table 1.** Genome-Wide Significant SNP-by-high Occupational Exposure Interactions in Association with the Level of FEV<sub>1</sub> in the Fixed-Effects Metaanalysis

Exposure*	SNP	Chr.	Annotation (refseq)	Effect allele	Metaanalysis				LifeLines (n = 5,070)				Vlgtwedde-Vlaardingen (n = 431)				
					P Value	b (ml)	r <sup>2</sup>	b (ml)	95% CI	P Value	MAF (%)	b (ml)	95% CI	P Value	MAF (%)		
Mineral dust	rs9376154	6	PDE7B (26kb 5')	G	2.94E-08	-381	0	-396	-555	-237	1.02E-06	8	-342	-597	-87	8.82E-03	8
Gases/fumes	rs70223081	5	NMUR2 (230kb 3')	C	1.94E-09	-422	77	-386	-528	-244	1.08E-07	8	-1020	-1593	-447	5.37E-04	8
Gases/fumes	rs7548373	1	IL10 (8kb 3')	T	7.56E-09	-606	0	-609	-822	-397	2.06E-08	5	-555	-1349	239	1.71E-01	6
Gases/fumes	rs17092559	14	SYNE3 (20kb 5')	A	3.74E-08	-264	65	-245	-341	-148	7.09E-07	20	-604	-1011	-197	3.84E-03	18

*Definition of abbreviations:* Chr. = chromosome; CI = confidence interval; r<sup>2</sup> = percentage of variation across studies; MAF = minor allele frequency; SNP = single-nucleotide polymorphism. Linear regression models were adjusted for sex, age, and height. Cohort-specific effect estimates for the LifeLines and Vlgtwedde-Vlaardingen cohorts are also shown. Interaction effects (b) and corresponding 95% confidence intervals (95% CI) are given in ml FEV<sub>1</sub>. MAF is given for the effect allele.

\*Prevalence of high exposure to mineral dust is 4% for LifeLines and 18% for Vlgtwedde-Vlaardingen; prevalence of high exposure to gases/fumes is 5% for LifeLines and 4% for Vlgtwedde-Vlaardingen.



**Figure 1.** Associations of low and high occupational exposure (no exposure was set as reference category) with the level of FEV<sub>1</sub> (ml) stratified by genotype in the Lifelines cohort (black dots) and Vlagtwedde-Vlaardingen cohort (gray dots). Linear regression models were adjusted for sex, age, and height. CI = confidence interval;  $n_{LL}$  = number of subjects in each stratum in the Lifelines cohort;  $n_{VV}$  = number of subjects in each stratum in the Vlagtwedde-Vlaardingen cohort.

clinically relevant size (i.e., subjects with high exposure to gases/fumes had up to 1,000 ml lower levels of FEV<sub>1</sub> compared with nonexposed subjects when carrying the risk allele; such effects were not observed in subjects with wild-type genotypes).

Another interesting SNP identified was located nearby interleukin 10 (*IL10*). Although the interaction effect did not reach nominal significance in the smaller Vlagtwedde-Vlaardingen cohort, effect estimates in both cohorts were large and of similar magnitude. Findings from the current study, together with findings from previous studies, suggest *IL10* is an important anti-inflammatory mediator with protective effects on lung function after exposure to noxious gases and fumes. For example, the number of bronchoalveolar lavage fluid polymorphonuclear leukocytes and nuclear factor- $\kappa$ B translocations were significantly greater in *IL10*-deficient mice compared with wild types after ozone exposure (8). Further, *IL10* expression increased in bronchial epithelium of healthy subjects when they were exposed to NO<sub>2</sub> (9). The SNP identified in the current study was not associated with expression of *IL10* in lung tissue, yet we were, unfortunately, not able to assess gene expression after stimulation by gases and

fumes. The pathway analysis suggested that natural killer cells, which produce IL-10 (10), may be involved in the development of impaired FEV<sub>1</sub> in the context of gases/fumes exposure, further supporting a mediating role of IL-10.

The main limitation of the current study is the small number of subjects with combinations of low-frequency genotypes and high exposure (Figure 1). However, we believe that the clear exposure–response patterns with clinically relevant effects on lung function levels, as well as the previously shown involvement of *NMU* and *IL10* in inflammatory responses, justifies further research into these genes as susceptibility loci for impaired FEV<sub>1</sub> in the context of gases/fumes exposure.

Of interest, none of the SNPs identified in the current study were identified in the previous study investigating ever- and never-smokers (1). In additional analyses in ever-smokers, we did not observe significant interactions ( $P < 0.05$ ) between identified SNPs and occupational exposure (data not shown). This justifies the rationale to assess SNP-by-occupational exposure interactions in a sample of never-smokers only. Absence of interactions in

ever-smokers does not imply they are nonexistent *per se*. In fact, interactions may not be detected if both tobacco smoke and occupational exposure are acting via the same biological pathways.

To conclude, this is the first study to identify novel and biologically plausible susceptibility loci associated with lung function impairment in never-smokers. These findings provide novel insights into biological pathways underlying disease development and pinpoint novel targets for further research into lung function impairment and chronic respiratory diseases such as chronic obstructive pulmonary disease in never-smokers. ■

**Author disclosures** are available with the text of this letter at [www.atsjournals.org](http://www.atsjournals.org).

**Acknowledgment:** The authors thank Cornelia M. van Duijn, Cleo C. van Diemen, and Najaf Amin for contributions to the study design and interpretation of data; Don D. Sin and Ke Hao for contributions to the lung eQTL database; and Roel Vermeulen for design and providing of the job exposure matrix (ALOHA+ JEM) for occupational exposure assessment.

Kim de Jong, Ph.D.  
Judith M. Vonk, Ph.D.  
Alen Faiz, Ph.D.  
Diana A. van der Plaats, M.Sc.  
Wim Timens, M.D., Ph.D.  
University of Groningen, University Medical Center Groningen  
Groningen, the Netherlands

Yohan Bossé, Ph.D.  
Laval University  
Québec, Canada

Hans Kromhout, Ph.D.  
University of Utrecht  
Utrecht, the Netherlands

Ivana Nedeljkovic, M.Sc.  
Erasmus University Medical Center  
Rotterdam, the Netherlands

Dirkje S. Postma, M.D., Ph.D.  
H. Marika Boezen, Ph.D.  
University of Groningen, University Medical Center Groningen  
Groningen, the Netherlands

ORCID IDs: 0000-0002-3948-1046 (K.d.J.); 0000-0003-1740-3538 (A.F.); 0000-0002-4146-6363 (W.T.); 0000-0002-3067-3711 (Y.B.); 0000-0002-4233-1890 (H.K.); 0000-0002-0370-1473 (I.N.); 0000-0001-7912-058X (D.S.P.).

## References

- de Jong K, Vonk JM, Timens W, Bossé Y, Sin DD, Hao K, Kromhout H, Vermeulen R, Postma DS, Boezen HM. Genome-wide interaction study of gene-by-occupational exposure and effects on FEV1 levels. *J Allergy Clin Immunol* 2015;136:1664–1672.
- Siedlinski M, van Diemen CC, Postma DS, Vonk JM, Boezen HM. Superoxide dismutases, lung function and bronchial responsiveness in a general population. *Eur Respir J* 2009;33:986–992.
- de Jong K, Boezen HM, Kromhout H, Vermeulen R, Postma DS, Vonk JM; LifeLines Cohort study. Pesticides and other occupational exposures are associated with airway obstruction: the LifeLines cohort study. *Occup Environ Med* 2014;71:88–96.
- Hao K, Bossé Y, Nickle DC, Paré PD, Postma DS, Laviolette M, Sandford A, Hackett TL, Daley D, Hogg JC, et al. Lung eQTLs to help reveal the molecular underpinnings of asthma. *PLoS Genet* 2012;8:e1003029.
- Zhang K, Cui S, Chang S, Zhang L, Wang J. i-GSEA4GWAS: a web server for identification of pathways/gene sets associated with traits by applying an improved gene set enrichment analysis to genome-wide association study. *Nucleic Acids Res* 2010;38:W90–5.
- Moriyama M, Fukuyama S, Inoue H, Matsumoto T, Sato T, Tanaka K, Kinjyo I, Kano T, Yoshimura A, Kojima M. The neuropeptide neuromedin U activates eosinophils and is involved in allergen-induced eosinophilia. *Am J Physiol Lung Cell Mol Physiol* 2006;290:L971–L977.
- Moriyama M, Sato T, Inoue H, Fukuyama S, Teranishi H, Kangawa K, Kano T, Yoshimura A, Kojima M. The neuropeptide neuromedin U promotes inflammation by direct activation of mast cells. *J Exp Med* 2005;202:217–224.
- Backus GS, Howden R, Fostel J, Bauer AK, Cho HY, Marzec J, Peden DB, Kleeberger SR. Protective role of interleukin-10 in ozone-induced pulmonary inflammation. *Environ Health Perspect* 2010;118:1721–1727.
- Pathmanathan S, Krishna MT, Blomberg A, Helleday R, Kelly FJ, Sandström T, Holgate ST, Wilson SJ, Frew AJ. Repeated daily exposure to 2 ppm nitrogen dioxide upregulates the expression of IL-5, IL-10, IL-13, and ICAM-1 in the bronchial epithelium of healthy human airways. *Occup Environ Med* 2003;60:892–896.
- Vivier E, Ugolini S. Regulatory natural killer cells: new players in the IL-10 anti-inflammatory response. *Cell Host Microbe* 2009;6:493–495.

Copyright © 2016 by the American Thoracic Society

## Down Under in the Coal Mines

To the Editor:

We read with interest the case series by Cohen and colleagues in a recent issue of the *Journal*, describing 13 cases of U.S. coal miners with rapidly progressive massive fibrosis (1). This confirms international data reporting an increase in incidence of pneumoconiosis from several countries. In Australia, several cases of coal workers' pneumoconiosis have recently been described in the state of Queensland, as well as new cases of complicated silicosis in New South Wales. This has been the topic of much media and public interest, and a Senate Select Committee inquiry has been set up to inquire into "black lung." Previously, the perception in Australia was that pneumoconiosis had been effectively eliminated.

As representatives of the Thoracic Society of Australia and New Zealand, the peak body involved in respiratory disease in the Antipodes, we are seriously concerned about the reemergence of pneumoconiosis. It is unacceptable that new cases of pneumoconiosis should be occurring in the 21st century at a time when the knowledge regarding prevention of such a disease is excellent. Lessons learned from the past seem to have been buried in the dusts of time. Australia has no centralized reporting of occupational lung disease, and it is almost impossible to assess the annual incidence or prevalence of well-known occupational respiratory diseases. Additionally, we contend that awareness of the other lung disorders also associated with coal dust exposure is limited among medical professionals. These include interstitial pulmonary fibrosis, chronic bronchitis and emphysema, and silicosis-related lung cancer.

Respiratory science arose from the miasmas of the past, and it was the early research in the coal fields that laid the foundations of